Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00171158 |
This extension II study will allow for further follow-up of the disease under treatment with imatinib mesylate and allow the patients to continue to receive imatinib mesylate.
Condition | Intervention | Phase |
---|---|---|
Philadelphia Positive Chronic Myeloid Leukemia in Myeloid Blast Crisis |
Drug: imatinib mesylate |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | An Extension Study of the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Patients (Male or Female ≥18 Years) With Ph + CML in Blast Crisis |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Exclusion Criteria
Other protocol-defined inclusion/exclusion criteria may apply.
Study ID Numbers: | CSTI571A0102E2 |
Study First Received: | September 12, 2005 |
Last Updated: | September 6, 2007 |
ClinicalTrials.gov Identifier: | NCT00171158 |
Health Authority: | United States: Food and Drug Administration |
Chronic Myelogenous Leukemia CML Philadelphia Chromosome Blast crisis Imatinib mesylate |
Imatinib Philadelphia Chromosome Blast Crisis Leukemia Chronic myelogenous leukemia |
Hematologic Diseases Myeloproliferative Disorders Leukemia, Myelogenous, Chronic, BCR-ABL Positive Leukemia, Myeloid Bone Marrow Diseases |
Neoplastic Processes Neoplasms Pathologic Processes Neoplasms by Histologic Type Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |
Therapeutic Uses Enzyme Inhibitors Protein Kinase Inhibitors Pharmacologic Actions Cell Transformation, Neoplastic |